467
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Transdermal delivery of alprazolam from a monolithic patch: formulation based on in vitro characterization

, , , &
Pages 1171-1178 | Received 22 Jul 2011, Accepted 21 Nov 2011, Published online: 29 Dec 2011

References

  • Shader RI, Greenblatt DJ. (1993). Use of benzodiazepines in anxiety disorders. N Engl J Med, 328:1398–1405.
  • Greenblatt DJ, von Moltke LL, Harmatz JS, Ciraulo DA, Shader RI. (1993). Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. J Clin Psychiatry, 54 Suppl:4–11; discussion 12.
  • Ranade V, Hollinger. (1996). Drug delivery systems. Boca Raton. CRC Press, inc., 177–208.
  • Guy R, Hadgraft J. (1989). Selection of drug candidates for transdermal delivery. Development issues and research initiatives. New York. Marcel Dekker.
  • Shaw JE Transdermal therapeutic systems in Dermal and Transdermal Absorption. Wissenschaftliche Verlagsgesel- lschaft. Stuttgart, 1982. 171–187.
  • Flynn GL, Stewart B. (1988). Percutaneous drug permeation: chosing candidates for transdermal development. Drug Develop Res, 13:85–169.
  • Sinha VR, Kaur MP. (2000). Permeation enhancers for transdermal drug delivery. Drug Dev Ind Pharm, 26:1131–1140.
  • Barry BW. (1988). Action of skin penetration enhancers-the Lipid Protein Partitioning theory. Int J Cosmet Sci, 10:281–293.
  • Potts R, Golden G, Francoeur M, Mak V, Guy R. (1991). Mechanism and enhancement of solute transport across the stratum corneum. J Controlled Release, 15:249–260.
  • Williams AC, Barry BW. (2004). Penetration enhancers. Adv Drug Deliv Rev, 56:603–618.
  • Nguyen Thien Hai Juyoung, Kim, Eun-Seok Park, Sang-Cheol Chi. (2008). Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm, 357:55–60.
  • Schurad B, Tack J, Lipp R. (2005). Evaluation of the transdermal permeation behavior of Proterguride from drug in adhesive matrix patches through hairless mouse skin. Drug Dev Ind Pharm, 31:505–513.
  • Boix Montañés A. Estudios de la permeación transdérmica de Alprazolam. Tesis doctoral 1998, Universidad de Barcelona.
  • Ogiso T, Iwaki M, Bechako K, Tsutsumi Y. (1992). Enhancement of percutaneous absorption by laurocapram. J Pharm Sci, 81:762–767.
  • Changshun Ren Liang, Fang, Lei Ling Qiang, Wang, Sihai Liu LiGang, Zhao, Zhonggui He. (2009). Design and in vivo evaluation o an indapamide transdermal patch. Int J Pharm, 370:129–135
  • FINAT Technical Handbook-Test Methods, 8th Edition FINAT Technical Handbook-Test Methods, 5th Edition 1999. Netherlands.
  • Rougier A. (1985). Permeation absorption – Transdermal water loss relationship in man in vivo. J Invest Dermatol, 84:66–68.
  • Winnonlin v.5.3 SCI software, Pharsight corporation. Scientific software, inc 2000.
  • Yamaoka K, Makawoa T. (1978). Application of akaike s information criteria (AIC) in the evaluation of linear pharmacokinetics equation. J Pharmacokinetic and Biopharm, 6:165–175.
  • Venkatakrishann K, Kerry E, Bruce L and Greenblatt D. (2005). Kinetics and dynamics of intravenous Adinazolam, N Desmethyl Adinazolam and Alprazolam in healthy volunteers. J Clin. Pharmacol, 45:529–327.
  • Tan HS, Pfister WR. (1999). Pressure-sensitive adhesives for transdermal drug delivery systems. Pharm Sci Technol Today, 2:60–69.
  • Guyot M, Fawaz F. (2000). Design and in vitro evaluation of adhesive matrix for transdermal delivery of propranolol. Int J Pharm, 204:171–182.
  • Venkatraman S, Gale R. (1998). Skin adhesives and skin adhesion. 1. Transdermal drug delivery systems. Biomaterials, 19:1119–1136.
  • Dimas DA, Dallas PP, Rekkas DD, Choulis NH. (2000). Effect of several factors on the mechanical properties of pressure-sensitive adhesives used in transdermal therapeutic systems. AAPS PharmSciTech, 1:E16.
  • Walters KA.. (ed). (2005). Dermatological and transdermal formulations. New York, Marcel Dekker.
  • Dermatological and transdermal formulations edited by Kenneth A., Walters.
  • Barry BW. (1987). Mode of action of permeation enhancers in human skin. J Controlled Release, 6:85–97.
  • Santus GC, Baker RW. (1993). Review of transdermal enhancer patent literature. J Controlled Release; 25:1–20.
  • Wiechers JW, Drenth BFH, Jonkman JHG et al. (1988). Percutaneous absorption, metabolism and elimination of the penetration enhancer Azone in humans after prolonged application under occlusion. Int Journal of Pharmaceutics, 47:43–49.
  • Carelli V, Di Colo G, Nannipieri E., and Serafini MF. (1994). Enhancement effects in the percutaneous absorption of alprazolam through human skin in vitro, 20:1673–1681.
  • Tanojo H, Bouwstra JA, Junginger HE &, Bodde. (1997). In vitro human skin barrier modulation by fatty acids: skin permeation as ointment in male volunteers. Arzneimittel forschung, 42:1122–1124.
  • Leoplod CS.(1998). How accurate is the determination of the relative bioavailability of transdermal drug formulations from pharmacodynamic response data?. Pharmaceutica Acta Helvetiae, 73:63–67

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.